Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
CNBC -

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.

In related news